Y-mabs reports second quarter sales increase for cancer drug

Despite booking a sales increase for children’s cancer treatment Danyelza, the Danish-American biotech firm is still running at a loss.

Photo: Mikel Bilbao/AP/Ritzau Scanpix

Danish-American biotech firm Y-mabs has just one market authorized product: Danyelza, a treatment for children with cancer type neuroblastoma.

Though the drug has not been enough to secure positive bottom-line figures, the company has managed to raise sales in the US, the only country where the treatment is approved, where Danyelza is widely used in cancer clinics.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs